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Background and Aims: The ghrelin receptor is one of the new therapeutic targets in the
cancer anorexia-cachexia syndrome. Previous studies revealed that plasma ghrelin levels
were high in patients with anorexia nervosa and low in obese subjects. We studied to
what extent ghrelin levels are related with anorexia and cachexia in patients with cancer.
Materials andMethods: Fasted ghrelin levels were determined as well as anorexia and
cachexia in patients with stage III/IV non-small cell lung cancer before chemotherapy.
Total plasma ghrelin was measured by radioimmunoassay. Anorexia was measured with
the FAACT-A/CS questionnaire (cut-off value ≤ 37). Cachexia was determined as >5%
weight loss (WL) in 6 months or >2% WL in 6 months in combination with low BMI
or low muscle mass. The Kruskal-Wallis test was performed to assess differences in
plasma ghrelin levels between four groups: patients with (+) or without (−) anorexia
(A) or cachexia (C). Multiple regression analyses were performed to assess differences
in plasma ghrelin levels between patients C+ and C− and patients with A+ and
A− (adjusted for age and sex).
Results: Forty patients with stage III (33%) or stage IV (68%) were recruited, of
which 50% was male. Mean age was 59.6 ± 10.3 years. Sixteen patients had
no anorexia or cachexia (A−C−), seven patients had both anorexia and cachexia
(A+C+), ten patients had anorexia without cachexia (A+C−) and seven patients had
cachexia without anorexia (A−C+). The levels of total plasma ghrelin were significantly
different between the four groups of patients with or without anorexia or cachexia
(p = 0.032): the A+C− patients had significantly higher ghrelin levels [median (IQR):
1,754 (1,404–2,142) compared to the A−C+ patients 1,026 (952–1,357), p = 0.003].
A+ patients had significantly higher ghrelin levels compared A− patients (C+ and
C− combined, β: 304, p = 0.020). Plasma ghrelin levels were not significantly different
in C+ patients compared to C− patients (A+ and A− combined, β: −99, p = 0.450).
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Conclusions: Patients with anorexia had significantly higher ghrelin levels compared to
patients without anorexia. We therefore hypothesize that patients with cancer anorexia
might benefit from treatment with a ghrelin receptor agonist to prevent WL and
deterioration in physical functioning.
Keywords: ghrelin, anorexia, cachexia, NSCLC, appetite, weight loss
INTRODUCTION
One of the promising new therapeutic targets for cancer-
associated weight loss (cachexia) is the ghrelin receptor. Ghrelin
is a 28-amino acid peptide that is the natural ligand for the
growth hormone secretagogue receptor-1a (Kojima et al., 1999).
Ghrelin plays an important role in several physiological processes
including increasing appetite by stimulating the production of
orexigenic neurons such as neuropeptide Y and agouti-related
protein-expressing neuron (Zhang and Garcia, 2015). Ghrelin
is produced by endocrine cells of the antrum during periods of
fasting (Kojima et al., 1999). Ghrelin levels are high in patients
with anorexia nervosa, low postprandial, and low in obesity
(Zhang and Garcia, 2015). Ghrelin levels increase in patients
who develop anorexia during chemotherapy but remain stable
in patients without anorexia during chemotherapy (Shimizu
et al., 2003). The evidence on changed ghrelin levels in cancer
cachexia however, appears to be inconclusive. Some studies
showed increased levels of ghrelin in patients with cachexia
compared to patients without cachexia (Shimizu et al., 2003;
Karapanagiotou et al., 2009), whereas other studies did not show
these differences (D’Onghia et al., 2007; Huang et al., 2007).
Randomized trials with ghrelin and ghrelin agonists have
shown promising results regarding improvements in appetite,
food intake, lean body mass, and quality of life of patients with
cancer cachexia (Garcia et al., 2013; Temel et al., 2016). Still,
no significant effect on physical functioning and survival was
demonstrated in two recent large randomized double blind phase
III trials (Temel et al., 2016).
As cachexia may be accompanied by a loss of appetite
(anorexia) and ghrelin is directly involved in the regulation of
hunger and appetite, it is hypothesized that the presence or
absence of anorexia may intervene in the association between
cancer cachexia and ghrelin (Shimizu et al., 2003). To test this
hypothesis, we studied associations between plasma ghrelin levels
and anorexia and cachexia in patients with advanced NSCLC.
MATERIALS AND METHODS
In this prospective study, patients with stage III or IV NSCLC
and starting with chemotherapy were recruited at the department
of Pulmonology of the VU University Medical Center in
Amsterdam, The Netherlands.
Exclusion criteria: systemic anticancer treatment in the past
month, clinically overt ascites or serious pitting edema, Diabetes
Mellitus, current use of high dose of corticosteroids, presence of
other active inflammatory disease (for example HIV or active
colitis) and insufficient command of the Dutch language. The
research protocol was approved by theMedical Ethics Committee
of the VU University Medical Center Amsterdam and the study
was performed in accordance with the ethical standards laid
down in the Declaration of Helsinki of 1975 as revised in 1983.
Written informed consent was obtained from all participants.
Measurements
Weight Loss and BMI
Body weight was measured (with patients wearing light indoor
clothes without shoes) within 0.2 kg on a calibrated scale (Seca
type 888). Self-reported body weight 6 months before inclusion
was assessed. A correction factor for clothes or clothes and
shoes (1.3 kg for females, 1.6 kg for males, 1.6 kg for females,
and 2.0 kg for males, respectively) was applied when necessary
(Frank and Dunlop, 2000). Relative weight change in 6 months
was calculated. Body height was measured using a stadiometer;
the patient was standing barefoot and height was determined to
the nearest cm. BMI was calculated as the ratio of body weight
(kg)/height (m)2.
SMI
Skeletal muscle area (cm2) was measured with SliceOmatic
Software V 5.0 (Tomovision, Magog, Canada) using routine CT
scans conducted for diagnostic purposes. The fourth thoracic
vertebra (T4) was used for the assessment of the skeletal muscle
area and in patients without evaluable T4 images, L3 images
were used. The structures of muscles were quantified based
on pre-established thresholds of Hounsfield Units (HU) (−29
to +150) of skeletal muscle tissue (Mitsiopoulos et al., 1998).
Cross-sectional areas (cm2) of the sum of all these muscles were
computed by summing tissue pixels and multiplying by the pixel
surface area for each patient. Skeletal Muscle Index (SMI) was
calculated as the ratio of skeletal muscle area (cm2)/height (m)2.
Cachexia
Cachexia was defined as:
– Weight loss >5% in 6 months or
– Weight loss >2% in 6 months in combination with BMI
<20 or
– Weight loss >2% in 6 months in combination with low
skeletal muscle index (SMI): L3: <55 cm2/m2 for males, <39
cm2/m2 for females (Fearon et al., 2011), T4: <66.0 cm2/m2
for males, <51.9 cm2/m2 for females (cut-off value p50 for T4,
comparable to L3 cut-off values in patients with SMI data on
both levels, data not published).
Anorexia
– The 12 items of the Anorexia/Cachexia subscale (A/CS) of
the Functional Assessment of Anorexia/Cachexia Therapy
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(FAACT) questionnaire (4th version, Dutch) (Ribaudo et al.,
2000) were scored on a five-point Likert scale (0 = not at all,
1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = very
much). For scoring the FAACT − A/CS, the FACIT manual
was applied (Cella, 1997). A lower score indicates less appetite.
A decreased appetite was defined as having a score of ≤37
(Blauwhoff-Buskermolen et al., 2016).
Ghrelin
Venous blood samples were collected between 7:30 and 9:00
a.m. after an overnight fast. Blood samples were collected using
EDTA tubes containing 250 KIU of aprotinin (BD Diagnostics,
Plymouth, UK), immediately placed on ice, and centrifuged.
Plasma was stored at −80◦C until assayed. Total plasma ghrelin
was determined by radioimmunoassay (RIA) (EMDMillipore
Corporation, Merck Life Sciences, KGaA, Darmstadt, Germany).
The intra-assay variation was below 4% and the inter-assay
variation was below 5%. The lower limit of quantitation (LOQ)
was 240 pg/mL. Analyses were performed at the Endocrine
Laboratory of the Department of Clinical Chemistry of the VU
University Medical Center.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows v.
23.0 (IBMCorporation, Armonk, NY, USA). Descriptive statistics
(count (%) and means ± SD or median (IQR), as appropriate)
were used to describe the study sample. An independent samples
Kruskal-Wallis Test was performed to assess differences in
ghrelin levels between four groups: patients with (+) or without
(−) anorexia (A) or cachexia (C) because of rather small
subgroups. Mann-Whitney U-tests were performed to assess the
largest difference between subgroups.
Linear regression analyses were performed with
logtransformed ghrelin levels to assess differences in ghrelin
levels for patients with and without anorexia and with and
without cachexia. In multiple regression analyses, adjustments
for age and sex were performed. A p ≤ 0.05 was considered
significant for all analyses.
RESULTS
Forty patients with stage III (33%) or stage IV (68%) were
recruited, of which 50%wasmale.Mean age was 59.6± 10.3 years
(Table 1).
Sixteen patients had no anorexia or cachexia (A−C−), seven
patients had both anorexia and cachexia (A+C+), ten patients
had anorexia without cachexia (A+C−) and seven patients had
cachexia without anorexia (A−C+). Of the 14 cachectic patients,
11 patients were diagnosed as such based on >5% weight loss.
Two patients were found to be cachectic based on 2–5% weight
loss in combination with low SMI and one patient was found to
be cachectic based on 2–5% weight loss in combination with low
BMI.
Figure 1 shows boxplots with median ghrelin levels for the
four groups. Ghrelin levels were significantly different between
the four groups (p = 0.032). In post-hoc analyses, the A+C−
patients had significantly higher ghrelin levels (median: 1,754
TABLE 1 | Patient characteristics (n = 40).
n (%)
Gender (males) 20 (50)
Age in years† 59.6 ± 10.3
Cancer stage
III 13 (33)
IV 27 (68)
BMI in kg/m2† 23.9 ± 4.0
FAACT-A/CS‡ 38 (35–42)
†
Mean ± sd,
‡
Median (IQR).
pg/mL, IQR 1,404–2,142) compared to the A−C+ patients
(median: 1,026 pg/mL, IQR 952–1,357, p= 0.003).
When cachexia and anorexia were analyzed separately, ghrelin
levels were not significantly different between patients with
(1,230 pg/mL; IQR 1,026–1,678, n = 14) or without cachexia
(1,462 pg/mL; IQR 1,212–2,092, n = 26; β = −99, p = 0.450
adjusted for age and sex). Patients with anorexia (n = 17)
had significantly higher ghrelin levels (1,624 pg/mL; IQR
1,391–2,102) compared to patients without anorexia (1,212
pg/mL; IQR 957–1,686), n = 23; β = 304, p = 0.020 adjusted for
age and sex).
DISCUSSION
In NSCLC, we found that patients with anorexia had significantly
higher plasma ghrelin levels compared to patients without
anorexia. In contrast to previous literature, we did not find
associations between ghrelin levels and cachexia.
We hypothesize that anorexia, and accompanying decreased
food intake, may lead to increased ghrelin levels in patients
with cancer, as endocrine cells of the antrum react to an empty
stomach with production of ghrelin (Kojima et al., 1999). This is
also supported by the fact that patients with anorexia nervosa also
have high ghrelin levels (Zhang and Garcia, 2015).
In patients with cancer, partial resistance to the orexigenic
effects of increased ghrelin levels has been hypothesized by
Garcia et al. (2005). They compare ghrelin resistance to insulin
resistance in type 2 diabetes mellitus, which is overcome by using
high doses of insulin. Further elevation in ghrelin levels (three-
to four-fold from baseline) may be able to increase appetite and
food intake (Garcia et al., 2005). Randomized trials with ghrelin
and ghrelin agonists have shown positive results regarding
improvements in appetite, food intake, lean body mass and
quality of life of patients with cancer cachexia (Garcia et al., 2013;
Temel et al., 2016). However, no significant effect on physical
functioning and survival was demonstrated in two well-designed
large phase III double blind randomized controlled trials (Temel
et al., 2016). As anorexia may be present in the pre-cachectic
stage and precede significant weight loss and deterioration in
physical functioning, future studies should consider treatment
with ghrelin in patients with cancer anorexia (for example, in the
stage of pre-cachexia) rather than patients with cachexia, in order
to study whether significant weight loss and deterioration in
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FIGURE 1 | Boxplots for fasting plasma ghrelin levels for patients with (+) or without (−) anorexia (A) and cachexia (C). The thick black horizontal line in
each boxplot represents the median value.
physical functioning can be prevented. Literature search resulted
in only one small study in seven patients with severe cancer
anorexia and this study had promising result: ghrelin infusion
resulted in a marked increase in energy intake of 31% and higher
meal appreciation scores (Neary et al., 2004). Future studies with
larger sample sizes with important end points such as quality of
life are of interest, which preferably also include measurement of
plasma ghrelin levels in order to learn more about the physiology
of ghrelin in patients with cancer cachexia.
In our study we measured only total ghrelin and not acylated
(“active”) ghrelin and deacylated (“inactive”) ghrelin separately.
The effects of ghrelin on appetite have been assigned to active
ghrelin, however the major form of ghrelin in serum is deacylated
ghrelin. In a study of Garcia and colleagues, active ghrelin levels
and the active to total ghrelin ratio were significantly increased
in subjects with cancer-induced cachexia, compared with cancer
patients without cachexia and non-cancer controls (Garcia et al.,
2005). Nevertheless, there is growing evidence supporting that
deacylated ghrelin is also closely linked with food intake and
gut motility (Chen et al., 2009). In future studies, acylated and
deacylated ghrelin should be analyzed separately in order to learn
more about the differences between the two subforms.
We need to remark that absolute reported concentrations of
plasma ghrelin are dependent on the analytical method used,
therefore we advise to be careful when comparing our reported
absolute values with literature on ghrelin levels in humans
measured with other methods. Also, when comparing our results
to the results of other studies, attention should be paid to the
used definitions of anorexia and cachexia. We have used the
most recent published classifications of anorexia and cachexia,
however this makes comparison to other studies (which used
other definitions of anorexia and cachexia) difficult.
This is the first study on plasma ghrelin levels and associations
with anorexia and cachexia in patients with cancer. In conclusion,
patients with anorexia had significantly higher ghrelin levels
compared to patients without anorexia, whereas no differences
were found between patients with and without cachexia. In future
studies, the effect of ghrelin (agonists) in the treatment of cancer
anorexia should be evaluated to prevent severe weight loss and
improve clinical outcomes such as physical functioning, quality
of life, and survival.
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